Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Firefly Neuroscience (AIFF) Change in Accured Expenses (2016 - 2025)

Firefly Neuroscience has reported Change in Accured Expenses over the past 15 years, most recently at $106000.0 for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $106000.0 for Q4 2025, down 77.59% from a year ago — trailing twelve months through Dec 2025 was -$952000.0 (down 179.18% YoY), and the annual figure for FY2025 was -$952000.0, down 179.18%.
  • Change in Accured Expenses for Q4 2025 was $106000.0 at Firefly Neuroscience, down from $126000.0 in the prior quarter.
  • Over the last five years, Change in Accured Expenses for AIFF hit a ceiling of $943000.0 in Q4 2023 and a floor of -$714000.0 in Q2 2025.
  • Median Change in Accured Expenses over the past 5 years was $43664.0 (2023), compared with a mean of $6930.2.
  • Biggest five-year swings in Change in Accured Expenses: skyrocketed 2793.37% in 2022 and later plummeted 3716.84% in 2024.
  • Firefly Neuroscience's Change in Accured Expenses stood at $85941.0 in 2021, then plummeted by 586.99% to -$418527.0 in 2022, then surged by 325.31% to $943000.0 in 2023, then tumbled by 49.84% to $473000.0 in 2024, then tumbled by 77.59% to $106000.0 in 2025.
  • The last three reported values for Change in Accured Expenses were $106000.0 (Q4 2025), $126000.0 (Q3 2025), and -$714000.0 (Q2 2025) per Business Quant data.